Dupilumab SAR231893 + Placebo + Non sedating H1-antihistamine
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Cold Urticaria
Conditions
Cold Urticaria
Trial Timeline
Dec 10, 2020 → Apr 20, 2023
NCT ID
NCT04681729About Dupilumab SAR231893 + Placebo + Non sedating H1-antihistamine
Dupilumab SAR231893 + Placebo + Non sedating H1-antihistamine is a phase 3 stage product being developed by Sanofi for Cold Urticaria. The current trial status is completed. This product is registered under clinical trial identifier NCT04681729. Target conditions include Cold Urticaria.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04681729 | Phase 3 | Completed |
| NCT04180488 | Phase 3 | Completed |
Competing Products
20 competing products in Cold Urticaria